Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial

Journal of Thoracic Oncology

Volumn 7, Issue 11, 2012, Pages 1645-1652

  Tsao, Anne S ^a   Liu, Suyu ^a   Lee, J Jack ^a   Alden, Christine ^a   Blumenschein, George ^a   Herbst, Roy ^b   Davis, Suzanne E ^a   Kim, Edward ^a   Lippman, Scott ^a   Stewart, David ^c   Tang, Xi Ming ^a   Wistuba, Ignacio ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b YALE CANCER CENTER   (United States)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Elderly patients; Non small cell lung cancer; Salvage therapy; Targeted agents

Indexed keywords

B RAF KINASE; BEXAROTENE; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; SORAFENIB; TUMOR MARKER; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; FEMALE; FLATULENCE; HUMAN; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; ONCOGENE K RAS; OVERALL SURVIVAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; VOMITING;

EID: 84867902025     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31826910ff     Document Type: Article

References (30)

1. Surveillance EaERSP: SEER cancer statistics review 1975-2007; available at: http://seer.cancer.gov. Accessed November 2011.
2. Lang K, Marciniak MD, Faries D, et al. Trends and predictors of frst-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009;63:264-270.
3. Quoix E, Zalcman G, Oster J P, et al.; Intergroupe Francophone de Cancérologie Thoracique. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-1088.
4. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:2350-2357.
5. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as frst-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001;6 Suppl 1:4-7.
6. Leighl NB, Zatloukal P, Mezger J, et al. Effcacy and safety of bevaci-zumab-based therapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol 2010;5:1970-1976.
7. Weiss GJ, Langer C, Rosell R, et al. Elderly patients beneft from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411.
8. Ramalingam SS, Dahlberg SE, Langer CJ, et al.; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with car-boplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
9. Kim ES, Herbst RS, Wistuba I, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
10. Gridelli C, Maione P, Castaldo V, Rossi A. Geftinib in elderly and unft patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003;89:1827-1829.
11. Hotta K, Ueoka H, Kiura K, et al. Safety and efficacy of gefi-tinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol 2005;44:717-722.
12. Wu CH, Fan WC, Chen YM, et al. Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. J Thorac Oncol 2010;5:376-379.
13. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-766.
14. Luciani A, Bertuzzi C, Ascione G, et al. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2009;66:94-96.
15. Smit EF, Dingemans AM, Thunnissen FB, Hochstenbach MM, van Suylen RJ, Postmus PE. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 2010;5:719-720.
16. Herbst RS, BlumenscheinG, Kim E, et al. Sorafenib Treatment Effcacy and Kras Biomarker Status in the Biomarker-Integrated Approaches of Targeted Therapy For Lung Cancer Elimination (Battle) Trial. Chicago, IL: Proc of the American Society of Clinical Oncology, 2010.
17. Heymach J V, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-4277.
18. Heymach J V, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as frst-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-5415.
19. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006;1:231-239.
20. Dacic S, Shuai Y, Yousem S, Ohori P, Nikiforova M. Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocar-cinomas. Mod Pathol 2010;23:159-168.
21. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3:111-116.
22. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051.
23. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55:1-14.
24. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic signifcance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73:294-300.
25. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-2093.
26. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic signifcance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997;3:1051-1058.
27. Khoury T, Alrawi S, Ramnath N, et al. Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 2009;10:58-66.
28. Buch S, Zhu B, Davis AG, et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog 2005;42:222-228.
29. Zhu J, Yu L, Zhan P, Song Y, Wang Q. The relationships between cyclin D1 expression and prognosis of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2010;13:803-808.
30. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-252.